We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDirecta Plus Regulatory News (DCTA)

Share Price Information for Directa Plus (DCTA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.70
Bid: 18.40
Ask: 19.00
Change: 0.00 (0.00%)
Spread: 0.60 (3.261%)
Open: 18.70
High: 18.70
Low: 18.70
Prev. Close: 18.70
DCTA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Notice of Results

27 Feb 2023 07:00

RNS Number : 0495R
Directa Plus PLC
27 February 2023
 

 

27 February 2023

 

Directa Plus plc

("Directa Plus" or the "Company")

 

Trading Update and Notice of Results

 

Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, is pleased to provide an update on trading for the year ended 31 December 2022 ("FY22") and on current trading and outlook.

 

On 2 December 2022, the Company announced that it expected FY22 revenues to be at least €10.0m, notwithstanding the fulfilment of orders totalling c.€2.0m being deferred into the new financial year due to the widely reported supply chain issues. Subject to completion of the audit process, the Group now expects revenues for FY22 to be not less than €10.8m, as a result of a strong performance in December, which represents a c.25% increase on the prior year.

 

This momentum has continued into 2023 with current trading in-line with market expectations1 and robust growth across all verticals supported by a strengthening pipeline of potential opportunities. The current order book for delivery in 2023 now stands at c. €8.8m, giving the Board confidence in the Company's continued growth in 2023.

 

Notice of results

The Company expects to announce its audited results for FY22 on 10 May 2023.

 

Giulio Cesareo, Founder and Chief Executive of Directa Plus, commented: "We made significant progress in FY22, fuelled by several contract wins and an increasingly supportive market backdrop as large supply chains increasingly look to incorporate our graphene into products to enhance performance and to provide more sustainable solutions. This year, we have demonstrated that our G+ technology has the ability to sit at the heart of a range of sectors and serve customers globally.

 

"The Company has entered FY23 in solid position, building on momentum from the end of the prior year. Our focus now is on developing our core verticals which are able to generate significant product demand and higher recurring revenue from customers. With an expanding network of customers and partners, a record order book and a strong balance sheet, I am confident in the Group's ability to deliver on its growth ambitions for the year ahead."

 

1)  The Company understands that consensus market expectations for the year ended 31 December 2023 are for revenues of 13.45m and an EBITDA loss of -1.7m (Source: Bloomberg)

 

Enquiries:

 

Directa Plus plc

+39 02 36714458

Giulio Cesareo, CEO

www.directa-plus.com 

Giorgio Bonfanti, CFO

 

 

Cenkos Securities plc (Nominated Adviser and Joint Broker)

+44 131 220 6939

Neil McDonald

Adam Rae

 

Singer Capital Markets Securities Limited (Joint Broker)

+44 20 7496 3069

Rick Thompson

Phil Davies

 

Alma PR (Financial PR and IR)

+44 20 3405 0205

Justine James

directaplus@almapr.co.uk 

Hannah Campbell

 

 

Notes to Editors

Directa Plus (www.directa-plus.com) is one of the largest producers and suppliers of graphene-based products for use in consumer and industrial markets. The Company's graphene manufacturing capability uses proprietary patented technology based on a plasma super expansion process. Starting from natural graphite, each step of Directa Plus' production process - expansion, exfoliation and drying - creates graphene-based materials and hybrid graphene materials ready for a variety of uses and available in various forms such as powder, liquid and paste.

 

This proprietary production process uses a physical process, rather than a chemical process, to process graphite into pristine graphene nanoplatelets, which enables Directa Plus to offer a sustainable, non-toxic product, without unwanted by-products. Directa Plus' products are made of hybrid graphene materials and graphene nano-platelets. The products (marketed as G+®) have multiple applications due to its properties. These G+® products can be categorised into various families, with different products being suitable for specific practical applications.

 

Directa Plus was established in 2005 and is based in Lomazzo (Como, Italy) and has been listed on the AIM market of the London Stock Exchange since May 2016. Directa Plus holds the Green Economy Mark from London Stock Exchange which recognises companies that contribute to the global green economy.

 

This trading update is provided in advance of the financial statements for the year ended 31 December 2022. The information and commentary provided is based on unaudited management accounts and other internal performance measures and is subject to concluding the routine annual accounting adjustments as well as any adjustments that arise as a result of the external audit process.  Certain statements made in this trading update are forward-looking statements. Such statements are based on current expectations and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results referred to in these forward-looking statements.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTNKQBDOBKDQBB
Date   Source Headline
15th Apr 20243:01 pmRNSNotification of major holdings
12th Apr 20247:00 amRNSGiPave® installed at Imola Circuit
25th Mar 20247:00 amRNSEUR 1,000,000 Loan Agreement Signed
22nd Mar 20247:00 amRNSCollaboration with UK-based Heathcoat Fabrics
26th Feb 20247:00 amRNSAcquisition of 49% minority interest in Setcar
31st Jan 20247:00 amRNSContract win with FORD Otosan
20th Dec 20237:00 amRNSAcquisition of groundbreaking technology
15th Dec 202311:44 amRNSExpansion of collaboration with Miguel Caballero
10th Nov 20237:00 amRNSChange of Nominated Adviser
27th Sep 20237:00 amRNSHalf-year Report
18th Sep 20237:00 amRNSStrategic collaboration with The SPECTRUM Group
8th Sep 20237:00 amRNSNotice of Interim Results
7th Sep 20237:00 amRNSSignificant contract secured with LIBERTY Galati
19th Jul 20237:00 amRNSProject tender awarded
29th Jun 20237:00 amRNSDirecta Plus receives two new Italian patents
22nd Jun 20237:00 amRNSNew concept for produced water decontamination
15th Jun 20235:40 pmRNSResult of AGM
8th Jun 20237:00 amRNSNew product launch
19th May 20237:00 amRNSPosting of Annual Report and Notice of AGM
10th May 20237:00 amRNSFinal Results
9th May 20237:00 amRNSNew contract with customer Alfredo Grassi
27th Apr 20237:00 amRNSNotice of Results Presentations
20th Mar 20237:00 amRNSNew Patent Granted
27th Feb 20237:00 amRNSTrading Update and Notice of Results
21st Dec 20227:00 amRNSNew significant contract with Pigmentsolution
5th Dec 20222:05 pmRNSSecond Price Monitoring Extn
5th Dec 20222:00 pmRNSPrice Monitoring Extension
2nd Dec 20227:00 amRNSTrading Update
29th Nov 20227:00 amRNSGrant Award
21st Nov 20227:00 amRNSDirectorate Change
28th Oct 20227:00 amRNSFirst Commercial Contract in Latin America
21st Oct 20227:00 amRNSFirst Major Commercial Contract for Gipave
17th Oct 20227:00 amRNSBoar Changes
17th Oct 20227:00 amRNSBoard Changes
29th Sep 202211:05 amRNSSecond Price Monitoring Extn
29th Sep 202211:00 amRNSPrice Monitoring Extension
29th Sep 20227:00 amRNSHalf-year Report
1st Sep 20227:00 amRNSTrading Statement
30th Aug 20227:00 amRNSUS Patent Notice
4th Aug 20227:00 amRNSPartnership Extension and US Patent Award
19th Jul 20227:00 amRNSAgreement with REDA Energy for Grafysorber
5th Jul 20227:00 amRNSSupply Agreement
22nd Jun 20227:00 amRNSGrant of Italian Filtration Patent
17th Jun 20223:40 pmRNSResult of AGM
17th Jun 20227:00 amRNSAGM Statement
19th May 20227:00 amRNSPosting of Annual Report and Notice of AGM
5th May 20227:00 amRNSFinal Results
22nd Apr 20227:00 amRNSPartnership to Develop Automotive Fabrics
4th Apr 20227:00 amRNSUS EPA Authorises Grafysorber for Use in US
7th Mar 20227:00 amRNSOxfordshire Starts Second Trial of GiPave

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.